|
| 36252154 | Treatment of Metastatic Colorectal Cancer: ASCO Guideline. | J Clin Oncol | 2023 |
| 37459754 | Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. | J Clin Oncol | 2023 |
| 37443348 | Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). | Br J Cancer | 2023 |
| 37339926 | Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer. | Cancer Control | 2023 |
| 37308125 | Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2023 |
| 37104870 | Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial. | Oncologist | 2023 |
| 37201999 | Disparities in gastrointestinal cancers. | J Natl Med Assoc | 2023 |
| 37433432 | NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023. | J Natl Compr Canc Netw | 2023 |
| 36521094 | Resource and Reimbursement Barriers to Comprehensive Cancer Care Delivery: An Analysis of Association of Community Cancer Centers Survey Data. | JCO Oncol Pract | 2023 |
| 36630671 | An Assessment of the Feasibility and Utility of an ACCC-ASCO Implicit Bias Training Program to Enhance Racial and Ethnic Diversity in Cancer Clinical Trials. | JCO Oncol Pract | 2023 |
| 36305992 | Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292). | Ann Surg Oncol | 2023 |
| 36200844 | Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs. | Oncologist | 2023 |
| 36194064 | Neoadjuvant therapy use and association with postoperative outcomes and overall survival in patients with extrahepatic cholangiocarcinoma. | J Surg Oncol | 2023 |
| 34820843 | Management of colorectal cancer during the COVID-19 pandemic: Recommendations from a statewide multidisciplinary cancer collaborative. | J Surg Oncol | 2022 |
| 35649196 | Anal Cancer: Emerging Standards in a Rare Disease. | J Clin Oncol | 2022 |
| 35732931 | Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort. | Cardiovasc Intervent Radiol | 2022 |
| 35641198 | Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). | Oncologist | 2022 |
| 35369396 | Role of Oncology Advanced Practitioners to Enhance Clinical Research. | J Adv Pract Oncol | 2022 |
| 35588469 | Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. | J Clin Oncol | 2022 |
| 36240850 | Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 36240850 | Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 36332157 | A Framework for Harmonization of Radiomics Data for Multicenter Studies and Clinical Trials. | JCO Clin Cancer Inform | 2022 |
| 36264382 | A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161. | Invest New Drugs | 2022 |
| 35952316 | Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial. | JCO Precis Oncol | 2022 |
| 35191970 | Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. | JAMA Netw Open | 2022 |
| 34995084 | Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). | J Clin Oncol | 2022 |
| 34865086 | Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. | J Natl Cancer Inst | 2022 |
| 32499156 | Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Investigation. | Acad Radiol | 2021 |
| 33629919 | An evaluation of <i>RAS</i> testing among metastatic colorectal cancer patients in the USA. | Future Oncol | 2021 |
| 33650740 | Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. | Oncologist | 2021 |
| 33845462 | Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 33724754 | Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 34950179 | Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling. | Liver Cancer | 2021 |
| 34902826 | Meeting Patients Where They Are: Policy Platform for Telehealth and Cancer Care Delivery. | J Natl Compr Canc Netw | 2021 |
| 34375560 | Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non-Safety-Net Centers. | JCO Oncol Pract | 2021 |
| 34536168 | Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. | Gastric Cancer | 2021 |
| 34104867 | Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). | JNCI Cancer Spectr | 2021 |
| 33939661 | Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database. | Pancreas | 2021 |
| 34363528 | Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. | Gastric Cancer | 2021 |
| 34340212 | Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 34030131 | Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 34374076 | Clinical trials as a path toward equity. | Cancer | 2021 |
| 32858111 | Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. | Int J Radiat Oncol Biol Phys | 2021 |
| 32911478 | Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. | Neuroendocrinology | 2021 |
| 31366576 | Failure to administer recommended chemotherapy: acceptable variation or cancer care quality blind spot? | BMJ Qual Saf | 2020 |
| 32030487 | Correction to: Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation. | Cardiovasc Intervent Radiol | 2020 |
| 31924737 | Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. | Clin Cancer Res | 2020 |
| 31740568 | Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. | Oncologist | 2020 |
| 32039734 | MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinoma. | J Transl Med | 2020 |
| 31852811 | Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). | Oncologist | 2020 |